What is Univ Health Svc's earnings per share (EPS)?

Univ Health Svc (UHS) reported diluted earnings per share of $23.10 for fiscal year 2025. This represents a 37.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Univ Health Svc Financials

UHS

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Univ Health Svc (UHS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 18 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI UHS FY2025 2026-05-07

Profit recovery is being funded by stronger cash generation and lower leverage, even as reinvestment remains heavy.

From FY2023 to FY2025, operating margin expanded from 8.2% to 11.5%, which means more of each revenue dollar reached operating profit instead of being absorbed by the cost base. At the same time, long-term debt moved lower and capital spending topped $1.0B in FY2025, so the earnings improvement appears to be funding both reinvestment and balance-sheet repair rather than relying on extra borrowing.

FY2025 free cash flow of $849M sat well below operating cash flow of $1.86B, which shows this is still a capital-intensive business where a large share of cash must go back into facilities before it becomes discretionary. That gap matters because reported profit can rise faster than spendable cash even when earnings quality is broadly sound.

The balance sheet looks more working-capital funded than cash-rich: the current ratio narrowed to 1.1x and cash was only $138M at year-end despite much larger profits. In practice, near-term flexibility depends more on collections and operating continuity than on holding a large cash cushion.

Financial Health Signals

Financial Health Score 54/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Univ Health Svc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Univ Health Svc has an operating margin of 11.5%, meaning the company retains $11 of operating profit per $100 of revenue. This strong profitability earns a score of 74/100, reflecting efficient cost management and pricing power. This is up from 10.6% the prior year.

Growth

Univ Health Svc's revenue grew 9.7% year-over-year to $17.4B, a solid pace of expansion. This earns a growth score of 66/100.

Leverage

Univ Health Svc has a moderate D/E ratio of 0.55. This balance of debt and equity financing earns a leverage score of 37/100.

Liquidity

Univ Health Svc's current ratio of 1.05 is below the typical benchmark, resulting in a score of 21/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Cash Flow

Univ Health Svc has a free cash flow margin of 4.9%, earning a moderate score of 49/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

Univ Health Svc earns a strong 20.5% return on equity (ROE), meaning it generates $20 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 79/100. This is up from 17.1% the prior year.

Altman Z-Score Grey Zone

2.96

Univ Health Svc scores 2.96, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

6/7

Univ Health Svc passes 6 of 7 computable financial strength tests (2 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

1.25x

For every $1 of reported earnings, Univ Health Svc generates $1.25 in operating cash flow ($1.9B OCF vs $1.5B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

12.8x

Univ Health Svc earns $12.8 in operating income for every $1 of interest expense ($2.0B vs $156.1M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$17.4B

YoY+9.7%

5Y CAGR+8.5%

10Y CAGR+6.7%

Univ Health Svc generated $17.4B in revenue in fiscal year 2025. This represents an increase of 9.7% from the prior year.

EBITDA

$2.6B

YoY+15.3%

5Y CAGR+6.9%

10Y CAGR+4.7%

Univ Health Svc's EBITDA was $2.6B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 15.3% from the prior year.

Net Income

$1.5B

YoY+30.4%

5Y CAGR+9.5%

10Y CAGR+8.1%

Univ Health Svc reported $1.5B in net income in fiscal year 2025. This represents an increase of 30.4% from the prior year.

EPS (Diluted)

$23.10

YoY+37.3%

5Y CAGR+16.0%

10Y CAGR+13.1%

Univ Health Svc earned $23.10 per diluted share (EPS) in fiscal year 2025. This represents an increase of 37.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$849.2M

YoY-24.4%

5Y CAGR-12.2%

10Y CAGR+2.1%

Univ Health Svc generated $849.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 24.4% from the prior year.

Cash & Debt

$137.8M

YoY+9.4%

5Y CAGR-35.4%

10Y CAGR+8.4%

Univ Health Svc held $137.8M in cash against $4.0B in long-term debt as of fiscal year 2025.

Dividends Per Share

$0.80

YoY+0.0%

Univ Health Svc paid $0.80 per share in dividends in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Shares Outstanding

N/A

Margins & Returns

Gross Margin

N/A

Operating Margin

11.5%

YoY+0.8pp

5Y CAGR-0.3pp

10Y CAGR-2.5pp

Univ Health Svc's operating margin was 11.5% in fiscal year 2025, reflecting core business profitability. This is up 0.8 percentage points from the prior year.

Net Margin

8.6%

YoY+1.3pp

5Y CAGR+0.4pp

10Y CAGR+1.0pp

Univ Health Svc's net profit margin was 8.6% in fiscal year 2025, showing the share of revenue converted to profit. This is up 1.3 percentage points from the prior year.

Return on Equity

20.5%

YoY+3.3pp

5Y CAGR+5.5pp

10Y CAGR+4.5pp

Univ Health Svc's ROE was 20.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 3.3 percentage points from the prior year.

Capital Allocation

R&D Spending

N/A

Share Buybacks

$968.0M

YoY+44.3%

5Y CAGR+36.2%

10Y CAGR+16.5%

Univ Health Svc spent $968.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 44.3% from the prior year.

Capital Expenditures

$1.0B

YoY+7.6%

5Y CAGR+6.8%

10Y CAGR+10.3%

Univ Health Svc invested $1.0B in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 7.6% from the prior year.

UHS Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$17.4B+9.7%	$15.8B+10.8%	$14.3B+6.6%	$13.4B+6.0%	$12.6B+9.4%	$11.6B
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$8.1B+7.5%	$7.5B+5.8%	$7.1B+5.1%	$6.8B+9.7%	$6.2B+9.8%	$5.6B
Operating Income	$2.0B+18.6%	$1.7B+43.1%	$1.2B+17.1%	$1.0B-26.4%	$1.4B+0.3%	$1.4B
Interest Expense	$156.1M-16.1%	$186.1M-10.0%	$206.7M+62.9%	$126.9M+51.7%	$83.7M-21.3%	$106.3M
Income Tax	$461.0M+37.7%	$334.8M+51.4%	$221.1M+5.7%	$209.3M-31.5%	$305.7M+2.1%	$299.3M
Net Income	$1.5B+30.4%	$1.1B+59.1%	$717.8M+6.2%	$675.6M-31.9%	$991.6M+5.0%	$944.0M
EPS (Diluted)	$23.10+37.3%	$16.82+64.4%	$10.23+11.9%	$9.14-22.7%	$11.82+7.6%	$10.99

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$4.5B+0.2%	$4.5B-0.2%	$4.5B+4.9%	$4.3B+4.5%	$4.1B-0.3%	$4.1B+3.8%	$4.0B+1.4%	$3.9B
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$2.1B+2.0%	$2.0B-1.2%	$2.1B+2.8%	$2.0B+3.3%	$2.0B+2.3%	$1.9B-0.3%	$1.9B+3.0%	$1.9B
Operating Income	$502.9M-2.8%	$517.2M-0.9%	$521.7M+4.3%	$500.3M+10.0%	$454.8M-3.7%	$472.5M+23.0%	$384.2M-12.0%	$436.4M
Interest Expense	$37.1M-12.0%	$42.2M+9.9%	$38.4M+8.7%	$35.4M-11.7%	$40.1M+0.8%	$39.7M-11.1%	$44.7M-8.7%	$48.9M
Income Tax	$110.4M-17.3%	$133.6M+13.4%	$117.8M+6.3%	$110.8M+12.1%	$98.8M-2.4%	$101.3M+33.9%	$75.6M-13.7%	$87.7M
Net Income	$348.7M-21.8%	$445.9M+19.6%	$373.0M+5.6%	$353.2M+11.5%	$316.7M-4.7%	$332.4M+28.5%	$258.7M-10.5%	$289.2M
EPS (Diluted)	$5.65	N/A	$5.86+7.9%	$5.43+13.1%	$4.80	N/A	$3.80-10.8%	$4.26

UHS Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$15.5B+7.3%	$14.5B+3.6%	$14.0B+3.5%	$13.5B+3.1%	$13.1B-2.8%	$13.5B
Current Assets	$3.4B+21.0%	$2.8B+0.2%	$2.8B+10.8%	$2.5B+12.1%	$2.3B-31.0%	$3.3B
Cash & Equivalents	$137.8M+9.4%	$126.0M+5.5%	$119.4M+16.2%	$102.8M-10.8%	$115.3M-90.6%	$1.2B
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$2.6B+19.5%	$2.2B-2.7%	$2.2B+10.9%	$2.0B+15.5%	$1.7B+1.0%	$1.7B
Goodwill	$4.0B+1.5%	$3.9B0.0%	$3.9B+0.6%	$3.9B-1.3%	$4.0B+2.1%	$3.9B
Total Liabilities	$8.3B+5.7%	$7.8B-0.2%	$7.8B+3.2%	$7.6B+8.1%	$7.0B-2.2%	$7.2B
Current Liabilities	$3.2B+46.6%	$2.2B+9.8%	$2.0B+5.2%	$1.9B-3.5%	$2.0B-20.0%	$2.5B
Long-Term Debt	$4.0B-10.3%	$4.5B-6.7%	$4.8B+1.3%	$4.7B+14.1%	$4.1B+17.5%	$3.5B
Total Equity	$7.3B+9.1%	$6.7B+8.4%	$6.1B+3.9%	$5.9B-2.8%	$6.1B-3.6%	$6.3B
Retained Earnings	$8.0B+8.4%	$7.4B+8.4%	$6.8B+4.1%	$6.5B-1.1%	$6.6B-2.1%	$6.7B

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$15.7B+1.0%	$15.5B+1.2%	$15.3B+2.4%	$15.0B+0.7%	$14.9B+2.8%	$14.5B+0.8%	$14.4B+2.0%	$14.1B
Current Assets	$3.5B+2.7%	$3.4B+4.6%	$3.3B+9.0%	$3.0B-2.8%	$3.1B+9.3%	$2.8B+0.5%	$2.8B+2.2%	$2.7B
Cash & Equivalents	$119.0M-13.6%	$137.8M+22.1%	$112.9M-18.0%	$137.6M+8.6%	$126.8M+0.6%	$126.0M+18.8%	$106.1M-17.6%	$128.8M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$2.7B+5.5%	$2.6B+0.7%	$2.6B+12.3%	$2.3B-4.5%	$2.4B+10.7%	$2.2B-1.6%	$2.2B+2.7%	$2.2B
Goodwill	$4.0B-0.2%	$4.0B0.0%	$4.0B+0.3%	$4.0B+0.8%	$3.9B+0.4%	$3.9B-0.8%	$4.0B+0.6%	$3.9B
Total Liabilities	$8.2B-0.4%	$8.3B+0.9%	$8.2B+2.7%	$8.0B-1.7%	$8.1B+3.7%	$7.8B+0.7%	$7.7B+2.1%	$7.6B
Current Liabilities	$3.2B+0.1%	$3.2B+2.5%	$3.2B+36.3%	$2.3B-0.6%	$2.3B+5.4%	$2.2B+9.9%	$2.0B-6.4%	$2.1B
Long-Term Debt	$4.0B-1.3%	$4.0B+1.4%	$4.0B-13.0%	$4.5B-1.5%	$4.6B+3.2%	$4.5B-3.3%	$4.6B+4.6%	$4.4B
Total Equity	$7.5B+2.6%	$7.3B+1.5%	$7.2B+2.0%	$7.0B+3.6%	$6.8B+1.8%	$6.7B+0.9%	$6.6B+1.9%	$6.5B
Retained Earnings	N/A	$8.0B	N/A	N/A	N/A	$7.4B	N/A	N/A

UHS Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$1.9B-9.8%	$2.1B+63.0%	$1.3B+27.3%	$996.0M+12.7%	$883.7M-62.6%	$2.4B
Capital Expenditures	$1.0B+7.6%	$943.8M+27.0%	$743.1M+1.2%	$734.0M-14.2%	$855.7M+17.0%	$731.3M
Free Cash Flow	$849.2M-24.4%	$1.1B+114.1%	$524.7M+100.3%	$262.0M+834.6%	$28.0M-98.3%	$1.6B
Investing Cash Flow	-$1.1B-17.5%	-$911.1M-19.4%	-$763.3M-17.9%	-$647.3M+29.2%	-$914.5M-13.9%	-$802.6M
Financing Cash Flow	-$749.7M+34.5%	-$1.1B-131.8%	-$493.9M-55.1%	-$318.4M+70.2%	-$1.1B-177.8%	-$384.9M
Dividends Paid	$51.3M-3.9%	$53.3M-3.8%	$55.5M-5.1%	$58.4M-11.3%	$65.9M+279.9%	$17.3M
Share Buybacks	$968.0M+44.3%	$670.8M+22.5%	$547.4M-34.3%	$832.9M-31.8%	$1.2B+490.6%	$206.7M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	$401.6M-30.1%	$574.7M+51.0%	$380.7M-30.7%	$549.0M+52.5%	$360.0M-45.3%	$658.4M+97.7%	$333.0M-51.0%	$679.3M
Capital Expenditures	$217.2M-22.8%	$281.2M+22.9%	$228.9M-14.0%	$266.0M+11.3%	$239.0M-2.8%	$245.9M-0.8%	$247.9M+2.7%	$241.4M
Free Cash Flow	$184.5M-37.1%	$293.5M+93.3%	$151.8M-46.4%	$283.0M+133.8%	$121.0M-70.7%	$412.5M+385.0%	$85.0M-80.6%	$437.9M
Investing Cash Flow	-$197.6M+11.8%	-$224.0M+16.9%	-$269.4M+11.9%	-$305.9M-12.8%	-$271.3M-30.4%	-$208.0M+21.7%	-$265.6M-9.4%	-$242.8M
Financing Cash Flow	-$221.9M+25.1%	-$296.1M-120.1%	-$134.5M+40.9%	-$227.7M-149.0%	-$91.4M+78.6%	-$426.8M-376.0%	-$89.7M+78.6%	-$419.5M
Dividends Paid	$13.0M+4.9%	$12.4M-2.6%	$12.7M-3.3%	$13.1M-3.0%	$13.5M+3.8%	$13.0M-3.2%	$13.5M-0.8%	$13.6M
Share Buybacks	$163.8M-53.5%	$352.0M+48.3%	$237.4M+53.0%	$155.2M-30.5%	$223.4M-10.7%	$250.2M+37.0%	$182.6M+90.4%	$95.9M

UHS Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	11.5%+0.8pp	10.6%+2.4pp	8.2%+0.7pp	7.5%-3.3pp	10.8%-1.0pp	11.8%
Net Margin	8.6%+1.3pp	7.2%+2.2pp	5.0%-0.0pp	5.0%-2.8pp	7.8%-0.3pp	8.2%
Return on Equity	20.5%+3.3pp	17.1%+5.5pp	11.7%+0.3pp	11.4%-4.9pp	16.3%+1.3pp	14.9%
Return on Assets	9.6%+1.7pp	7.9%+2.7pp	5.1%+0.1pp	5.0%-2.6pp	7.6%+0.6pp	7.0%
Current Ratio	1.05-0.2	1.27-0.1	1.40+0.1	1.33+0.2	1.14-0.2	1.32
Debt-to-Equity	0.55-0.1	0.67-0.1	0.78-0.0	0.80+0.1	0.68+0.1	0.56
FCF Margin	4.9%-2.2pp	7.1%+3.4pp	3.7%+1.7pp	2.0%+1.7pp	0.2%-13.9pp	14.1%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	11.2%-0.3pp	11.5%-0.1pp	11.6%-0.1pp	11.7%+0.6pp	11.1%-0.4pp	11.5%+1.8pp	9.7%-1.5pp	11.2%
Net Margin	7.8%-2.2pp	9.9%+1.6pp	8.3%+0.1pp	8.3%+0.5pp	7.7%-0.4pp	8.1%+1.6pp	6.5%-0.9pp	7.4%
Return on Equity	4.7%-1.5pp	6.1%+0.9pp	5.2%+0.2pp	5.0%+0.4pp	4.7%-0.3pp	5.0%+1.1pp	3.9%-0.5pp	4.5%
Return on Assets	2.2%-0.6pp	2.9%+0.4pp	2.4%+0.1pp	2.4%+0.2pp	2.1%-0.2pp	2.3%+0.5pp	1.8%-0.3pp	2.1%
Current Ratio	1.08+0.0	1.05+0.0	1.03-0.3	1.29-0.0	1.32+0.0	1.27-0.1	1.39+0.1	1.28
Debt-to-Equity	0.53-0.0	0.550.0	0.55-0.1	0.65-0.0	0.680.0	0.67-0.0	0.70+0.0	0.68
FCF Margin	4.1%-2.4pp	6.5%+3.2pp	3.4%-3.2pp	6.6%+3.7pp	2.9%-7.1pp	10.0%+7.9pp	2.1%-9.1pp	11.2%

Similar Companies

Encompass Health Corp EHC

$11.2B

Tenet Healthcare Corp THC

$20.1B

Fresenius Med Cr FMS

$13.2B

Ensign Group Inc ENSG

$10.1B

Hca Healthcare Inc HCA

$84.8B

Frequently Asked Questions

What is Univ Health Svc's annual revenue?

Univ Health Svc (UHS) reported $17.4B in total revenue for fiscal year 2025. This represents a 9.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Univ Health Svc's revenue growing?

Univ Health Svc (UHS) revenue grew by 9.7% year-over-year, from $15.8B to $17.4B in fiscal year 2025.

Is Univ Health Svc profitable?

Yes, Univ Health Svc (UHS) reported a net income of $1.5B in fiscal year 2025, with a net profit margin of 8.6%.

What is Univ Health Svc's EBITDA?

Univ Health Svc (UHS) had EBITDA of $2.6B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Univ Health Svc have?

As of fiscal year 2025, Univ Health Svc (UHS) had $137.8M in cash and equivalents against $4.0B in long-term debt.

What is Univ Health Svc's operating margin?

Univ Health Svc (UHS) had an operating margin of 11.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Univ Health Svc's net profit margin?

Univ Health Svc (UHS) had a net profit margin of 8.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does Univ Health Svc pay dividends?

Yes, Univ Health Svc (UHS) paid $0.80 per share in dividends during fiscal year 2025.

What is Univ Health Svc's return on equity (ROE)?

Univ Health Svc (UHS) has a return on equity of 20.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Univ Health Svc's free cash flow?

Univ Health Svc (UHS) generated $849.2M in free cash flow during fiscal year 2025. This represents a -24.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Univ Health Svc's operating cash flow?

Univ Health Svc (UHS) generated $1.9B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Univ Health Svc's total assets?

Univ Health Svc (UHS) had $15.5B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Univ Health Svc's capital expenditures?

Univ Health Svc (UHS) invested $1.0B in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Does Univ Health Svc buy back shares?

Yes, Univ Health Svc (UHS) spent $968.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

What is Univ Health Svc's current ratio?

Univ Health Svc (UHS) had a current ratio of 1.05 as of fiscal year 2025, which is considered adequate.

What is Univ Health Svc's debt-to-equity ratio?

Univ Health Svc (UHS) had a debt-to-equity ratio of 0.55 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Univ Health Svc's return on assets (ROA)?

Univ Health Svc (UHS) had a return on assets of 9.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Univ Health Svc's Altman Z-Score?

Univ Health Svc (UHS) has an Altman Z-Score of 2.96, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Univ Health Svc's Piotroski F-Score?

Univ Health Svc (UHS) has a Piotroski F-Score of 6 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Univ Health Svc's earnings high quality?

Univ Health Svc (UHS) has an earnings quality ratio of 1.25x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Univ Health Svc cover its interest payments?

Univ Health Svc (UHS) has an interest coverage ratio of 12.8x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Univ Health Svc?

Univ Health Svc (UHS) scores 54 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.